Chris Hwang – Scientific Advisor and ex-CTO, Transcenta
After 25 years at Genzyme and Sanofi, Chris Hwang joined a biotech startup in China in 2016 to develop advanced bioprocessing technologies that reduce cost of goods while maintaining reliable…
Transcenta is a global biotherapeutics company that fully integrates antibody-based biotherapeutics discovery, R&D and manufacturing.
Transcenta is competitive in new biologics R&D and manufacture.
Our proprietary Immune Tolerance Breaking Technology is capable of generating antibodies with diverse epitopes. Multiple partnerships on antibody discovery and co-development has been achieved based on this technology.
With our flexible manufacturing facility, we are able to accelerate product development and improve product quality control while significantly reducing the cost of production.
As of 2019, Transcenta has secured approximately USD 137 million from well-known investors including Lilly Asia Ventures, ARCH Venture Partners, Temasek, Sequoia Capital, Tengyue Partners, Taikang and Hillhouse Capital.
Contact
Address: Room 501, Building B6, 218 Xinghu Street, Suzhou Industrial Park (SIP) bioBAY, Suzhou, China
Website: http://www.transcenta.com/
After 25 years at Genzyme and Sanofi, Chris Hwang joined a biotech startup in China in 2016 to develop advanced bioprocessing technologies that reduce cost of goods while maintaining reliable…
We last spoke with Xueming Qian, CEO and co-founder of the biotech Transcenta in 2019. Since then, the company has seen some important milestones: listing on the Hong Kong Stock…
Transcenta’s Xueming Qian outlines the new company’s origins, the space it seeks to fill within the highly competitive Chinese oncology market, and where Chinese biotech stands globally in 2019. …
After 25 years at Genzyme and Sanofi, Chris Hwang joined a biotech startup in China in 2016 to develop advanced bioprocessing technologies that reduce cost of goods while maintaining reliable…
Despite an adverse funding panorama and looming geopolitical tensions, Chinese biotech is still thriving. Companies originating in China are advancing promising pipelines, going public, looking beyond China’s borders with a…
We last spoke with Xueming Qian, CEO and co-founder of the biotech Transcenta in 2019. Since then, the company has seen some important milestones: listing on the Hong Kong Stock…
Transcenta’s Xueming Qian outlines the new company’s origins, the space it seeks to fill within the highly competitive Chinese oncology market, and where Chinese biotech stands globally in 2019. …
See our Cookie Privacy Policy Here
